Form 4: Aprea Therapeutics Director Receives Equity Grant

Director Marc Duey acquired 3,135 restricted stock units and 12,555 stock options as part of an annual compensation grant.

Summary

• Director Marc Duey was granted 3,135 restricted stock units (RSUs) on June 16, 2026.
• The director also received an option to purchase 12,555 shares of common stock at an exercise price of $0.7293 per share.
• Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued board service.
• Following these transactions, the director's direct beneficial ownership increased to 259,290 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention mechanism for board members via time-based vesting.

Negatives

• Minor dilution to existing shareholders resulting from the issuance of new equity awards.

Risks

• Vesting is subject to continued service on the board, creating potential turnover risk if the director departs before June 16, 2027.

Future Outlook

The equity grants are subject to standard vesting conditions, with full vesting expected on June 16, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
• The grant size is typical for non-executive director compensation packages in the industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on June 16, 2027.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation